Beta Bionics priced an underwritten public offering of 7,652,175 common shares at $17.25 per share, alongside pre-funded warrants for 1,043,484 shares at $17.2499 each. Gross proceeds from the offering are expected to be about $150.0M before fees and expenses, the company said. The offering is expected to close on or about Sept. 17, 2026. Shares of Beta Bionics fell 7% in early trading on Wednesday.
Beta Bionics, Inc. Common StockBeta Bionics priced a $150M underwritten public offering of ~7.65M shares at $17.25, a dilutive equity financing that sent shares down 7%.
